1 not yet recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
Follow EnhanceAR-Seq: new trials by email Literature Review of EnhanceAR-Seq trials Research Report on EnhanceAR-Seq
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| [18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC) 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one, FTT-PET/CT, EnhanceAR-Seq - Metastatic Prostate Cancer, Prostate Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 75 | 2026-11-01 | 2026-10-21 |
Washington University School of Medicine (1)
United States (1)
R01CA306993 (1)